Neurogene (NGNE) Shares Outstanding (Diluted Average) (2017 - 2026)

Neurogene has reported Shares Outstanding (Diluted Average) for 10 years, with the latest figure at $22.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 6.24% year-over-year to $22.3 million; the trailing twelve-month figure through Mar 2026 stood at $22.3 million (up 6.24% YoY), and the FY2025 full-year result was $21.3 million, up 21.4% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $22.3 million, up from $21.3 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $55.2 million in Q2 2022, with the low at $441498.0 in Q3 2023.
• Historically, Shares Outstanding (Diluted Average) has averaged $20.1 million across 5 years, with a median of $17.6 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Diluted Average) sank 99.19% — and 2024, when it jumped 3739.98%.
• Neurogene's Shares Outstanding (Diluted Average) stood at $11.1 million in 2022, then slumped by 57.86% to $4.7 million in 2023, then surged by 277.22% to $17.6 million in 2024, then gained by 21.4% to $21.3 million in 2025, then climbed by 4.59% to $22.3 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $22.3 million (Q1 2026), $21.3 million (Q4 2025), and $21.1 million (Q3 2025), per Business Quant data.